Get the Stockscreener App
29.53
1.57%
-0.47
Pre-market:
29.98
0.45
+1.52%
Rapt Therapeutics Inc stock is traded at $29.53, with a volume of 554.71K.
It is down -1.57% in the last 24 hours and up +23.30% over the past month.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
See More
Previous Close:
$30.00
Open:
$29.75
24h Volume:
554.71K
Relative Volume:
1.84
Market Cap:
$488.36M
Revenue:
$3.25M
Net Income/Loss:
$-116.80M
P/E Ratio:
-9.682
EPS:
-3.05
Net Cash Flow:
$-98.17M
1W Performance:
+0.65%
1M Performance:
+23.30%
6M Performance:
+322.15%
1Y Performance:
+108.55%
1-Day Range:
$28.86
$30.00
1-Week Range:
$25.50
$42.39
52-Week Range:
$5.6652
$42.39
Rapt Therapeutics Inc Stock (RAPT) Company Profile
Name
Rapt Therapeutics Inc
Sector
Industry
Phone
(650) 489-9000
Address
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Compare RAPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPT
Rapt Therapeutics Inc
|
29.53 | 496.13M | 3.25M | -116.80M | -98.17M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.39 | 108.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
463.43 | 60.82B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.95 | 61.02B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
817.32 | 50.01B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
310.81 | 34.05B | 4.56B | -176.77M | 225.30M | -1.7177 |
Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-20-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-13-25 | Initiated | Barclays | Overweight |
| Sep-26-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-30-25 | Upgrade | JP Morgan | Underweight → Neutral |
| May-22-25 | Resumed | H.C. Wainwright | Buy |
| Dec-26-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-13-24 | Downgrade | Stifel | Buy → Hold |
| Nov-11-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-14-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-10-24 | Downgrade | Barclays | Overweight → Equal Weight |
| May-10-24 | Downgrade | Guggenheim | Buy → Neutral |
| Feb-22-24 | Downgrade | UBS | Buy → Neutral |
| Feb-21-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-21-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-21-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Feb-20-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-16-24 | Initiated | Evercore ISI | Outperform |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Sep-14-23 | Initiated | Berenberg | Buy |
| Aug-09-23 | Initiated | Stifel | Buy |
| Jun-15-23 | Initiated | Barclays | Overweight |
| Jan-04-23 | Initiated | Guggenheim | Buy |
| Dec-01-22 | Initiated | Goldman | Buy |
| Sep-21-22 | Initiated | CapitalOne | Overweight |
| May-24-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-09-21 | Initiated | JP Morgan | Overweight |
| Aug-12-21 | Initiated | SVB Leerink | Outperform |
| Jun-21-21 | Initiated | Piper Sandler | Overweight |
| Jun-01-20 | Initiated | H.C. Wainwright | Buy |
| May-19-20 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-13-20 | Initiated | ROTH Capital | Buy |
| Nov-25-19 | Initiated | BMO Capital Markets | Outperform |
| Nov-25-19 | Initiated | UBS | Buy |
| Nov-25-19 | Initiated | Wells Fargo | Outperform |
View All
Rapt Therapeutics Inc Stock (RAPT) Latest News
Analyzing RAPT Therapeutics Inc. with multi timeframe chartsQuarterly Earnings Report & Verified Trade Idea Suggestions - newser.com
Why retail investors favor RAPT Therapeutics Inc. stockIPO Watch & Weekly Watchlist for Hot Stocks - newser.com
Tick level data insight on RAPT Therapeutics Inc. volatilityWeekly Earnings Recap & AI Driven Stock Price Forecasts - newser.com
Risk adjusted return profile for RAPT Therapeutics Inc. analyzedDividend Hike & AI Enhanced Trade Execution Alerts - newser.com
Published on: 2025-10-27 02:57:37 - newser.com
Can RAPT Therapeutics Inc. recover in the next quarterPortfolio Risk Summary & Comprehensive Market Scan Reports - newser.com
Is RAPT Therapeutics Inc. stock a buy for dividend growthJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
What indicators show strength in RAPT Therapeutics Inc.Trade Performance Summary & Consistent Profit Focused Trading Strategies - newser.com
Published on: 2025-10-27 00:59:41 - newser.com
Does RAPT Therapeutics Inc. (0RA) stock trade below intrinsic value2025 Analyst Calls & Momentum Based Trading Signals - newser.com
Published on: 2025-10-26 23:23:14 - newser.com
Is RAPT Therapeutics Inc. stock reversal real or fakeDay Trade & Reliable Breakout Stock Forecasts - newser.com
Published on: 2025-10-26 21:27:10 - newser.com
Published on: 2025-10-26 20:42:00 - newser.com
Why RAPT Therapeutics Inc. (0RA) stock could break out in 2025Quarterly Earnings Report & Technical Entry and Exit Alerts - newser.com
Is RAPT Therapeutics Inc. (0RA) stock dividend growth reliableJuly 2025 Closing Moves & Verified Momentum Stock Ideas - newser.com
Published on: 2025-10-26 15:06:18 - newser.com
Leading vs lagging indicators on RAPT Therapeutics Inc. performanceInsider Selling & Technical Entry and Exit Tips - newser.com
Published on: 2025-10-26 10:44:52 - newser.com
Wells Fargo Boosts RAPT Therapeutics (RAPT) PT to $48 on Promising Anti-IgE Drug Data - Insider Monkey
Published on: 2025-10-26 00:53:27 - newser.com
Rapt Therapeutics Inc Stock (RAPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):